QA ameliorated UC through the inhibition of two TLR4‐NF‐κB and NF‐κB‐INOS‐NO signaling pathways, which results in the reduction of colitis complications, including oxidative stress, inflammation, apoptosis, and histopathological injuries in rats. Here, TLR4 is linked to colitis.